HOPE: Clinical, Pathology, and Imaging Project for Brain Tumors
Clinical, patHOlogical and Imaging Project of nEuro-oncology (HOPE)
This project collects clinical records, MRI scans, and pathology data from people with glioma and other primary brain tumors to build large databases for improving diagnosis and care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 70000 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Beijing Tiantan Hospital Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT05859659 on ClinicalTrials.gov |
What this trial studies
HOPE will create a multivariate retrospective CNS tumor database of over 50,000 cases (including about 10,000 glioma) that integrates clinical information, preoperative MRI, and molecular pathology. A parallel prospective glioma cohort of roughly 3,000 cases will capture advanced MRI sequences and standardized postoperative follow-up. The project is observational and non-interventional, requiring informed consent and high-quality imaging, with exclusions for prior treatment or other neurological diseases. Data will be collected at Beijing Tiantan Hospital and standardized to support radiogenomic analyses, prognostic modeling, and future research use.
Who should consider this trial
Good fit: Ideal candidates are patients with a pathologically confirmed glioma who can undergo MRI with sufficient image quality, provide informed consent, and complete clinical follow-up.
Not a fit: People without a pathological glioma diagnosis, those with prior surgery/biopsy or prior radiation or chemotherapy before enrollment, those with other neurological diseases, or those unable to tolerate MRI or complete follow-up are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, the database could enable better imaging-based diagnosis, more accurate prognosis models, and more personalized treatment planning for people with glioma.
How similar studies have performed: Large public imaging-pathology initiatives (for example TCGA and BraTS) have demonstrated that integrated databases can advance glioma radiogenomics and prognostic research, so this approach builds on prior successes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * (1) a clear diagnosis of glioma based on pathological results; * (2) The MRI sequence is complete and there are no obvious artifacts in the image; * (3) The patient signs an informed consent form Exclusion Criteria: * (1) Suffering from other neurological diseases; * (2) Prior to enrollment, surgery or biopsy, or a history of radiation therapy or chemotherapy; * (3) Unable to complete clinical scoring and related laboratory tests, unable to complete follow-up; * (4) Unable to tolerate MRI examination; Poor image quality, such as motion artifacts.
Where this trial is running
Beijing, Beijing Municipality
- Beijing Tiantan Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Principal investigator: Yaou Liu, Doctor — Beijing Tiantan Hospital
- Study coordinator: Yaou Liu, Doctor
- Email: yaouliu80@163.com
- Phone: +86 1059975396
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.